Clinical trials in Marseille – page 12

1 490 clinical trials in Marseille, France across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Marseille at a glance

1 490

clinical trials

Research sites7

Quick filters

1 490 trials in Marseille

Open in trial search

Colorectal cancer metastatic

Recruiting

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Idiopathic pulmonary fibrosis

Recruiting

A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis

Investigational

A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis

Investigational

France

Participants:18–64 years · 65+ years
Substances:HUMANISED IGG1 LALAPS-YTE MONOCLONAL ANTIBODY AGAINST LYSOPHOSPHATIDIC ACID RECEPTOR 1
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Hormone-refractory prostate cancer+1

Recruiting

A study evaluating the efficacy and safety of inavolisib and enzalutamide in patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo

A study evaluating the efficacy and safety of inavolisib and enzalutamide in patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Abiraterone
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Peripheral arterial occlusive disease+5

Recruiting

A study comparing one month versus one year of aspirin and clopidogrel treatment in patients with chronic limb-threatening ischemia after below-the-knee vascular therapy.

Registered drug

A study comparing one month versus one year of aspirin and clopidogrel treatment in patients with chronic limb-threatening ischemia after below-the-knee vascular therapy.

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Clopidogrel
Sponsor:Fondation Hopital Saint Joseph

Contact Research Centre

Hidradenitis

Recruiting

A safety and efficacy study of SAR445399 in adults with moderate to severe hidradenitis suppurativa

Investigational

A safety and efficacy study of SAR445399 in adults with moderate to severe hidradenitis suppurativa

Investigational

France

Participants:18–64 years · 65+ years
Substances:SAR445399
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

A study of ficerafusp alfa and nivolumab in patients with head and neck cancer who did not respond to platinum-based chemotherapy.

Registered drugNo placebo

A study of ficerafusp alfa and nivolumab in patients with head and neck cancer who did not respond to platinum-based chemotherapy.

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Nivolumab
Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Contact Research Centre

Breast cancer metastatic

Recruiting

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Letrozole
Sponsor:Olema Pharmaceuticals Inc.

Contact Research Centre

Polyneuropathy

Recruiting

A study to evaluate the safety and effectiveness of nucresiran and vutrisiran in patients with hereditary transthyretin amyloidosis with polyneuropathy

Registered drugNo placebo

A study to evaluate the safety and effectiveness of nucresiran and vutrisiran in patients with hereditary transthyretin amyloidosis with polyneuropathy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Vutrisiran
Sponsor:Alnylam Pharmaceuticals Inc.

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study of ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

Registered drug

Study of ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Azacitidine
Sponsor:Kura Oncology Inc.

Contact Research Centre

Squamous cell carcinoma of lung+6

Recruiting

A study to evaluate the safety and effectiveness of BNT324 and BNT327 in patients with advanced lung cancer

InvestigationalNo placebo

A study to evaluate the safety and effectiveness of BNT324 and BNT327 in patients with advanced lung cancer

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:BNT327
Sponsor:BioNTech SE

Contact Research Centre

Non-small cell lung cancer

Recruiting

A study comparing the effectiveness and safety of datopotamab deruxtecan and docetaxel in adults with advanced or metastatic non-squamous non-small cell lung cancer

Registered drugNo placebo

A study comparing the effectiveness and safety of datopotamab deruxtecan and docetaxel in adults with advanced or metastatic non-squamous non-small cell lung cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Docetaxel
Sponsor:AstraZeneca AB

Contact Research Centre

A study evaluating the efficacy and safety of secukinumab compared to a drug combination in patients with severe Takayasu arteritis.

Recruiting

Registered drugNo placebo

A study evaluating the efficacy and safety of secukinumab compared to a drug combination in patients with severe Takayasu arteritis.

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Adalimumab
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Marseille

What the registry says about research in the country

01 Oncology Research

Studies focusing on innovative treatments for head and neck squamous cell carcinoma, examining novel therapies and combinations with radiotherapy. Research includes investigations into endometrial cancer and bladder cancer treatments.

Advanced tumor treatments
Immunotherapy combinations
Targeted therapies

Particular emphasis on combining immunotherapy with conventional treatments for improved patient outcomes.

02 Cardiovascular and Metabolic Disorders

Innovative research addressing heart failure prevention and treatment of acute myocardial infarction. Studies include new approaches for managing hypertriglyceridemia and chronic kidney disease.

Preventive cardiology
Emergency cardiac care
Metabolic conditions

Focus on developing novel therapeutic approaches and improving patient outcomes in cardiovascular health.

03 Neurological Conditions

Clinical investigations into multiple sclerosis treatment strategies and management of essential tremor. Research includes innovative approaches for Dravet Syndrome and neurological disorders.

Movement disorders
Autoimmune conditions
Seizure management

Emphasis on developing targeted therapies for various neurological conditions affecting both adults and children.

Back to France All countries